{
    "clinical_study": {
        "@rank": "15047", 
        "acronym": "GAO", 
        "arm_group": [
            {
                "arm_group_label": "Copaxone", 
                "description": "Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)"
            }, 
            {
                "arm_group_label": "OCT", 
                "description": "Healthy controls"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, observational, single-blinded, longitudinal, 24-month OCT study of\n      the evolution of axonal loss, as evidenced by loss of RNFLT and TMV, in RRMS patients\n      treated with GA and in healthy controls."
        }, 
        "brief_title": "Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary aim of this study is to explore whether treatment with Copaxone may decrease\n      accumulation of axonal loss, as measured by retinal nerve fiber layer thickness (RNFLT) on\n      optical coherence tomography (OCT) in patients with RRMS over 24 months and compared to a\n      reference population of healthy controls.\n\n      The secondary objective of this study is to investigate the effect of GA on total macular\n      volume (TMV) on OCT in patients with RRMS over 24 months. We will also explore how the\n      24-month changes of RNFLT and TMV on OCT relate to progression of disability, as measured by\n      Expanded Disability Status Scale (EDSS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  MS patients diagnosed with clinically definite MS according to the McDonald criteria\n             (Polman et al., 2005)\n\n          -  Starting GA monotherapy (20mg/day sc) at the time of the OCT scan\n\n          -  Having baseline clinical OCT scan that included RNFLT and TMV assessment at the start\n             of the GA\n\n          -  Having baseline clinical OCT scan that included RNFLT and TMV assessment (healthy\n             controls)\n\n          -  MS patients having a RR disease course (Lublin and Reingold, 1996)\n\n          -  Age 18-65 (healthy controls will be matched to MS patients for age and sex)\n\n          -  Signed informed consent at the 24-month follow-up\n\n          -  None of the exclusion criteria\n\n        Exclusion Criteria:\n\n          -  Patients who had a relapse within 30 days prior to OCT scan date\n\n          -  Patients who received steroid treatment within 30 days prior to OCT scan date\n\n          -  Women who are pregnant, lactating or of childbearing age who do not consent to\n             approved contraceptive use during the study\n\n          -  MS patients who used other imunomodulatory or immunosuppressant treatment other than\n             GA during the follow-up (e.g., IFN-\u03b2, mitoxantrone, cyclophosphamide, cladribine,\n             fludarabine, cyclosporine, total body, azathioprine, methotrexate, IVIG, cellcept,\n             natalizumab, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with relapsing remitting multiple sclerosis Healthy controls without known\n        neurological problems."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017808", 
            "org_study_id": "GA-OCT"
        }, 
        "intervention_browse": {
            "mesh_term": "Copolymer 1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "OCT", 
            "Copaxone", 
            "Multiple sclerosis", 
            "relapsing-remitting"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "rmelia@bnac.net", 
                "last_name": "Rebecca Melia, BS", 
                "phone": "716-859-7040"
            }, 
            "contact_backup": {
                "email": "rzivadinov@bnac.net", 
                "last_name": "Robert Zivadinov, MD, PhD", 
                "phone": "716-859-7031"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14203"
                }, 
                "name": "Buffalo Neuroimaging Analysis Center"
            }, 
            "investigator": {
                "last_name": "Robert Zivadinov, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months", 
        "overall_contact": {
            "email": "rmelia@bnac.net", 
            "last_name": "Rebecca Melia, BS", 
            "phone": "716-859-7040"
        }, 
        "overall_contact_backup": {
            "email": "rzivadinov@bnac.net", 
            "last_name": "Robert Zivadinov, MD, PhD", 
            "phone": "716-859-7031"
        }, 
        "overall_official": {
            "affiliation": "SUNY University at Buffalo", 
            "last_name": "Robert Zivadinov, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will have an OCT retinal health will  be determined by degree of axonal loss.", 
            "measure": "Retinal health in multiple sclerosis patients prescribed copaxone", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017808"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University at Buffalo", 
            "investigator_full_name": "Robert Zivadinov, MD, PhD", 
            "investigator_title": "Director, Buffalo Neuroimaging Analysis Center, Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Investigating the effect of copaxone on total macular volume on OCT in patients with RRMS. Exploring progression of disability as measured by Expanded Disability Status Scale (EDSS).", 
            "measure": "Measuring disability progression", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "University at Buffalo", 
        "sponsors": {
            "collaborator": {
                "agency": "Teva Pharmaceuticals USA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University at Buffalo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}